Peer-reviewed work carrying the Hemavive affiliation, and the provisional filings that protect the platform's product architecture, therapeutic applications and enabling manufacturing.
Zanetti G, Legut M, Chen A, Fathi F, Suek N, Teteloshvili N, Li HW, Ding X, Traum D, Kaestner KH, Hoang RE, Sewell AK, Parent AV, Creusot RJ, Sykes M, Khosravi-Maharlooei M.
Accepted for publication in JCI Insight. Preprint: bioRxiv, 20 February 2026; 2026.02.19.706929.
Nikhat S, Bose S, Khosravi-Maharlooei M.
Biology (Basel), 10 July 2026; 15(14):1125.
Four provisional applications filed in 2026, designed to protect core product architecture, therapeutic applications and enabling manufacturing.
Programmable immune visibility plus regulated therapeutic function in HSPCs.
Primary donor HSPCs with permanent, temporary or developmental immune visibility for banked products — including radiation / marrow failure and SCID / IEI.
Donor-specific engineered HSPCs to establish mixed chimerism and donor-specific tolerance; not necessarily banked.
Autologous or hypoimmune donor HSPCs carrying regulated immunoregulatory or pro-regenerative payloads for inflammatory and tissue compartments.
Closed and distributed HSPC processing and engineering — preserving future automation and manufacturing optionality.
Applications span radiation and marrow failure, SCID / IEI, hemoglobinopathies, transplant tolerance, and autoimmunity / neuroinflammation. Provisional applications establish priority; they are not granted patents.
Detailed technical materials and preclinical datasets are available under CDA / NDA.